Further defining the genetic architecture of Alzheimer's disease

Lead Research Organisation: Cardiff University
Department Name: School of Medicine

Abstract

Alzheimer's disease is a common debilitating disorder which affects individuals, families and communities. Just under half a million people have Alzheimer's disease (AD) in the UK with an estimated cost of £23 billion per year. It is also estimated that the numbers with AD will double in the next generation. It is vital we understand what causes this disease and develop therapies to prevent, delay and treat it. Finding genes which affect the development of AD is an important means to pinpoint processes that are going wrong and contributing to the death of brain cells, which characterises this disease and underlies the symptoms of memory loss and general cognitive degeneration. Over the last 25 years approximately a quarter of the genetic contributors to disease have been identified and our group have played a pivotal role in this and have recently discovered 8 of the 10 common risk variants for AD. This has made us re-think some of our ideas about the specific processes which contribute to disease. These genes cluster together to form groups, implicating processes like our immune response, how we process lipids like cholesterol in the brain and a specific process called endocytosis, which brings large molecules into cells and affects their transport within cells, such as neurons. But over half the genetic contribution to disease is yet to be found. We propose a programme of research which builds on our current strengths, focusing on identifying rare genetic variants of moderate to strong effect observed in the coding regions of genes. We will perform a large, powerful study in which we compare 300,000 DNA variants from throughout the human genome, in 20,000 AD cases and 49,000 controls. Through sample collection and collaboration, we will enrich our clinical samples to include 1000 individuals with early onset AD. This group are more likely to have rare genetic changes of moderate to large effect on their development of disease. This experiment has an excellent chace of identifying new risk genes for AD and producing targets better suited to model disease in human cells and produce new therapeutics. We will also facilitate future research by producing a bio-bank of cell lines suitable for human modelling of disease using the latest stem cell technology (inducible pluripotent stem cells: iPSC) and making this available to the research community and pharmaceutical companies.

Technical Summary

Approximately half a million people have Alzheimer's disease (AD) in the UK, incurring an annual care cost of £23 billion. 35 million have dementia world-wide and it is estimated that these numbers will double by 2040. Identifying genes that affect the development of AD is important in pin-pointing potential disease mechanisms, testing new therapeutics and in predicting individual risk of disease development. Our programme of research will focus on identifying rare, exonic susceptibility variants of moderate/strong effect, using novel, powerful, genome-wide approaches and extended and enriched clinical samples. We will undertake a case-control association study comprising 20,000 AD cases and 49,000 controls focusing on coding regions throughout the genome, using the Illumina exome chip. We will also collect a sample of 500 cases with early-onset AD (EOAD), an uncommon form of the disease (<5% cases) that manifests before the age of 65, and in which heritability is especially high (92-100%). We will sequence the exomes of the 500 EOAD individuals and analyse them together with 500 EOAD exomes available to us through collaboration. Susceptibility variants identified will be replicated in an independent sample of 10,000 AD cases and 10,000 controls. We aim to detect rare variants of larger effect than those observed for common susceptibility variants; these effects should prove easier to model and will facilitate the further understanding of disease mechanisms and the development of new therapeutics. We will combine all genetic data we have generated to extend and develop complex analyses including pathway analysis, sub-phenotypic analysis and cross-disease analysis. Finally, we will establish and extend research resources such as DNA and additional sample banking from all EOAD cases collected, and iPSC programmable cell lines from 50 EOAD cases to facilitate functional analyses. This resource will be made available to research and pharmaceutical communities.

Planned Impact

The ultimate aim of this research is to build a better understanding of the causes of Alzheimer's disease and in so doing, provide a platform for the development of targeted treatments and preventions. Thus the main potential beneficiaries are those with the disease and those at risk of developing the disease. AD has a high impact on society. The cost of caring for individuals with the disease is around £23billion per year, with a substantial component due to the social cost of funding practical care and the cost to society of losing skilled family members from the workforce, who care for relatives directly. Thus AD affects more than just the individuals diagnosed. It affects the family and the wider community. We know that the number of people with AD will double in the next generation, so this problem is getting worse. The timescale on identifying new drug targets and translating this into the clinic is typically 10-15 years.
Another potential impact of our research is in characterising individual risk profiles, which could be useful in improving the efficiency of clinical trials. For example, a particular drug under trial could be more beneficial for those with one type of risk profile compared to others. Therefore, defining the variation in these profiles could aid more efficient clinical trials, resulting in increased numbers and better, targeted drugs coming to clinic. This could potentially have a considerable economic impact for the pharmaceutical sector. Most drugs fail to get through clinical trials, producing an enormous cost burden for pharmaceutical companies. We are working with pharmaceutical and other commercial companies to produce a test of genetic risk for use in clinical trials and are confident that this could be commercially available in the next couple of years.
As we further define the genetic architecture of AD, predicting one's risk of developing disease will become a more realistic outcome. Currently, genetic testing is only helpful for hose with known autosomal dominant mutations. This programme is likely to result in several new variants of moderate to strong effect, which may also be used to predict disease in others. The timeline for this impact would be within the next 5 years.
Current animal and cellular models of AD have major limitations. This programme aims to identify genetic variants that have moderate to strong individual effects on disease development. Not only will these provide better animal models than the common risk variants identified so far, but will allow multiple genes to influence models, which may better reflect essential disease components. Currently, most mouse models based upon known disease mutations do not recapitulate the full range of disease symptoms. As we discover more genuine disease causing/risk variants, our ability to produce more realistic disease models will improve. This is likely to have significant impact on the success of commercial testing of new drugs by providing more accurate models. Mouse models could be available within a year of discovery and will be facilitated by our current funded collaborations- Neuromouse funded by the MRC.
In addition, iPSC models that reflect specific genetic risk profiles will be available to the research and commercial communities, directly from this research. This will provide relevant human cellular models to facilitate translation and be available during the course of the grant.
We also aim to identify genes that affect symptoms/characteristics of AD, such as psychosis, depression and rate of decline, which again can be used to target specific disease mechanisms through drug therapy. Similarly, we will test for common disease variants across diseases such as ALS, PD, cardiovascular disease and diabetes. These findings may be used to support drug development for the prevention of or treatment for individuals with or at risk of developing a broad range of diseases. Timelines of 10-15 years, as described above.

Organisations

Publications

10 25 50
 
Description "Talented Women for a Successful Wales" report commissioned by the Welsh Government
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in a advisory committee
URL http://gov.wales/docs/det/report/160308-women-in-science-en.pdf
 
Description Academy Medical Sciences Council Member
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description Academy Medical Sciences Fellow
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Academy Medical Sciences Wales Ambassador
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description Associate Director, UK Dementia Research Institute (UKDRI)
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Chief Scientific Advisor, Welsh Government
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Deputy Director DPUK
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Membership of a guideline committee
 
Description EPAD LCS sample access committe
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Medicines Discovery Institute MDI
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description NMHRI management
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description A high content analysis platform for analysing dementia-associated genetic variation
Amount £108,300 (GBP)
Funding ID Co-applicant 
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2017 
End 09/2017
 
Description ABBUK Brains for Dementia Research Programme (extension)
Amount £404,390 (GBP)
Funding ID 504291 
Organisation Alzheimer’s Brain Bank UK 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2013 
End 03/2018
 
Description Centre for Ageing and Dementia Research (CADR)
Amount £386,341 (GBP)
Organisation Welsh Assembly 
Sector Public
Country United Kingdom
Start 04/2018 
End 03/2020
 
Description Centre for Ageing and Dementia Research (CADR)
Amount £1,200,000 (GBP)
Funding ID 507827 
Organisation Welsh Assembly 
Sector Public
Country United Kingdom
Start 04/2015 
End 03/2018
 
Description Centre for Ageing and Dementia Research - 2 Year Extension
Amount £1,200,000 (GBP)
Funding ID 514840 
Organisation Government of Wales 
Sector Public
Country United Kingdom
Start 04/2018 
End 03/2020
 
Description Defining genetic, polygenic and environmental risk for Alzheimer's disease using multiply powerful cohorts, focussed epigenetics and stem cells
Amount £810,998 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 01/2014 
End 12/2017
 
Description Expanding DPUK genetics and integrating with inflammation/immunity research
Amount £100,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 03/2018 
End 03/2019
 
Description IDEA - Integrated DEmentiA research enviornment
Amount £1,882,982 (GBP)
Funding ID MR/M009076/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 04/2015 
End 03/2016
 
Description Imaging immunity in the genetic risk for Alzheimer's disease
Amount £191,580 (GBP)
Organisation Government of Wales 
Department Welsh European Funding Office
Sector Public
Country United Kingdom
Start 10/2018 
End 09/2021
 
Description In vivo imaging of Tau distribution in the brain
Amount £44,743 (GBP)
Organisation Welsh Local Government Association 
Sector Public
Country United Kingdom
Start 01/2016 
End 03/2017
 
Description Investigating PLCG2 and P522R variant PLCG2 in human IPSC models of dementia
Amount £275,000 (GBP)
Organisation Eisai Inc 
Start 06/2018 
End 05/2020
 
Description Moondance Centre for Early Onset Alzheimer's Disease
Amount £500,000 (GBP)
Organisation The Moondance Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2015 
End 07/2020
 
Description PERADES: Defining genetic, polygenic and environmental risk of Alzheimer's disease using multiple power cohorts, focussed epigentics and stem cell metabolomics
Amount £389,000 (GBP)
Funding ID ARUK-PG2014-1 
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2013 
End 11/2016
 
Description The development and implementation of polygenic risk algorithms for stratifying individuals for future cognitive decline due to Alzheimer's disease in non-symptomatic and early cognitive impaired subjects
Amount £293,296 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 03/2018 
End 02/2020
 
Description The development and implementation of polygenic risk algorithms for stratifying individuals for future cognitive decline due to Alzheimers disease
Amount £298,040 (GBP)
Funding ID 2018/20180222 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 03/2018 
End 03/2020
 
Description Therapeutic targeting of impaired lysosomal flux in Alzheimer's disease
Amount £136,502 (GBP)
Funding ID MR/P007651/1 
Organisation Network of Centres of Excellence in Neurodegeneration (COEN) 
Sector Public
Country United Kingdom
Start 08/2016 
End 10/2017
 
Description Therapeutic targeting of impaired lysosomal flux in Alzheimer's disease
Amount £136,502 (GBP)
Funding ID MR/P007651/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 08/2016 
End 07/2018
 
Title AD Genetics Scotland 
Description Blood samples are collected from participants and sent directly from research sites to European Collection of Authenticated Cell Cultures (ECACC), a Culture Collection of Public Health England. Upon arrival, ECACC process the blood and transform into cell lines- peripheral blood lymphocytes (PBLs) and Lymphoblastoid cell lines (LCLs). Cell lines are frozen and stored at ECACC until they are required by the team at Cardiff. 
Type Of Material Biological samples 
Year Produced 2018 
Provided To Others? No  
Impact Ongoing collection of samples, no publications to date. 
 
Title BAC cell lines 
Description Bacterial method to insert gene mutations of interest into cell lines 
Type Of Material Cell line 
Provided To Others? No  
Impact none yet 
 
Title CRISPR generated cell lines 
Description Cell lines created using genome editing tool 
Type Of Material Cell line 
Provided To Others? No  
Impact none yet 
 
Title EOAD cohort 
Description We are collecting a biological sample of early onset Alzheimer's disease individuals for research. This includes phenotypic data and biological data and is set to become the largest EOAD biobank in the world. 
Type Of Material Biological samples 
Provided To Others? No  
Impact This earlier more aggressive form of the disease will be studied in order to shed light on disease mechanisms and prospective therapies. 
 
Title Human Stem Cell Modelling of Brain Disease 
Description Cellular models in vitro 
Type Of Material Model of mechanisms or symptoms - in vitro 
Provided To Others? No  
Impact unknown 
 
Title Polygenic score 
Description With 80,000 variants included to create a measure of risk of Alzheimer's disease, the polygenic score is an excellent predictive tool to determine case/control status with high accuracy. The polygenic score encompasses the majority of genetic risk of disease, and can be fine-tuned to identify the pathways involved in disease, for example, immune cell activity or endocytosis. 
Type Of Material Model of mechanisms or symptoms - human 
Year Produced 2016 
Provided To Others? Yes  
Impact We are working to translate this method from the basic science environment in which it was created into a predictive tool used to select participants for clinical trials, based on their disease status and type. We are currently in discussions with a number of potential collaborators to take this forward. 
 
Title DPUK Genomics portal 
Description The DPUK Genetics portal provides a collaborative platform for individuals, DPUK cohorts and the wider research community to share and access research outputs from genetic research. The platform provides two key tools for finding, sharing and analysing genetic data; The Results Registry tool, accessible via the main DPUK web portal, allows searching and uploading of genetic results data. This tool provides a rich set of search tools specific to genetic data and includes visualisation using the popular JBrowse genomic browser. This tool will allow users to share this data. This can be done under secure data transfer agreements if necessary. The second tool is the Genetic Data Browser this is available exclusively within the secure DPUK infrastructure. This will allow users to create cross-cohort comparison studies based on genotypic datasets and linked phenotypic data. This tool provides an interactive dashboard which can pull in phenotypic data and genetic markers from GWAS data and allow users to intuitively explore, combine and export patient cohorts. 
Type Of Material Database/Collection of data 
Year Produced 2017 
Provided To Others? Yes  
Impact The DPUK Genetics portal, housed on the DPUK platform, allows non bioinformatic-expert users to explore components of genetic data within a secure environment. We have provided access to an international consortium, GERAD, via the DPUK data portal. This is a dataset of over 18,000 cases and controls (detailed in Table 2), as well as over 5,600 samples to date submitted to the EADB, the European AD DNA bank for deciphering the missing heritability of Alzheimer's disease 
URL https://portal.dementiasplatform.uk/
 
Title GERAD Exome chip data 
Description Dataset from Illumina Exome chip platform (version 1.0 and v1.1), approximately 6,000 cases and 4,000 controls 
Type Of Material Database/Collection of data 
Year Produced 2014 
Provided To Others? Yes  
Impact papers in press 
 
Title IGAP dataset 
Description Mega-meta analysis data of over 17,000 AD cases and 30,000 controls 
Type Of Material Database/Collection of data 
Year Produced 2013 
Provided To Others? Yes  
Impact Lambert et al. 2013 (PMID:24162737), Escott-Price et al. 2014(in press), Farrer et al. 2014 (submitted) 
 
Description ADES Collaboration 
Organisation Erasmus University Medical Center
Country Netherlands 
Sector Academic/University 
PI Contribution A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this.
Collaborator Contribution as above
Impact n/a
Start Year 2016
 
Description ADES Collaboration 
Organisation Hospital de Sant Pau
Country Spain 
Sector Hospitals 
PI Contribution A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this.
Collaborator Contribution as above
Impact n/a
Start Year 2016
 
Description ADES Collaboration 
Organisation National Institute of Health and Medical Research (INSERM)
Country France 
Sector Public 
PI Contribution A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this.
Collaborator Contribution as above
Impact n/a
Start Year 2016
 
Description ADES Collaboration 
Organisation Pasteur Institute, Lille
Country France 
Sector Charity/Non Profit 
PI Contribution A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this.
Collaborator Contribution as above
Impact n/a
Start Year 2016
 
Description ADES Collaboration 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this.
Collaborator Contribution as above
Impact n/a
Start Year 2016
 
Description ADES Collaboration 
Organisation University of Bonn
Country Germany 
Sector Academic/University 
PI Contribution A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this.
Collaborator Contribution as above
Impact n/a
Start Year 2016
 
Description ADES Collaboration 
Organisation University of Pennsylvania
Country United States 
Sector Academic/University 
PI Contribution A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this.
Collaborator Contribution as above
Impact n/a
Start Year 2016
 
Description ADES Collaboration 
Organisation VU University Medical Center
Country Netherlands 
Sector Academic/University 
PI Contribution A way to make aware our different institutions and funders of that we are working hard to a better organisation of the AD genetic field worldwide and we need strong support for this.
Collaborator Contribution as above
Impact n/a
Start Year 2016
 
Description AZAPT 
Organisation Arizona Association for Play Therapy
Country United States 
Sector Charity/Non Profit 
PI Contribution MOLECULAR BIOLOGY, data analysis, cell culture
Collaborator Contribution MOLECULAR BIOLOGY, data analysis, cell culture
Impact none yet
Start Year 2014
 
Description Brains for Dementia Research 
Organisation King's College London
Department Clinical Neuroscience
Country United Kingdom 
Sector Academic/University 
PI Contribution Overall Management of BDR Centre, recruitment and Brain Banking
Collaborator Contribution Overall Management of BDR Centre, recruitment and Brain Banking
Impact BDR aims to set a gold standard for brain donation by coordinating brain banks across the country and providing high quality tissue to researchers. We hope to enable more people to get involved in brain donation, thus boosting the number of brains available for this important research. BDR is unique because every brain donor is monitored throughout their later life. This means that a complete medical history is available to accompany their donated brain tissue. This is crucial to allow researchers to make the most of donated tissue. BDR run an online database of brain tissue. Researchers can search the database and apply to BDR for samples.
Start Year 2013
 
Description Brains for Dementia Research 
Organisation Newcastle University
Department Institute for Ageing and Health
Country United Kingdom 
Sector Academic/University 
PI Contribution Overall Management of BDR Centre, recruitment and Brain Banking
Collaborator Contribution Overall Management of BDR Centre, recruitment and Brain Banking
Impact BDR aims to set a gold standard for brain donation by coordinating brain banks across the country and providing high quality tissue to researchers. We hope to enable more people to get involved in brain donation, thus boosting the number of brains available for this important research. BDR is unique because every brain donor is monitored throughout their later life. This means that a complete medical history is available to accompany their donated brain tissue. This is crucial to allow researchers to make the most of donated tissue. BDR run an online database of brain tissue. Researchers can search the database and apply to BDR for samples.
Start Year 2013
 
Description Brains for Dementia Research 
Organisation University of Bristol
Department Dementia Research Group
Country United Kingdom 
Sector Academic/University 
PI Contribution Overall Management of BDR Centre, recruitment and Brain Banking
Collaborator Contribution Overall Management of BDR Centre, recruitment and Brain Banking
Impact BDR aims to set a gold standard for brain donation by coordinating brain banks across the country and providing high quality tissue to researchers. We hope to enable more people to get involved in brain donation, thus boosting the number of brains available for this important research. BDR is unique because every brain donor is monitored throughout their later life. This means that a complete medical history is available to accompany their donated brain tissue. This is crucial to allow researchers to make the most of donated tissue. BDR run an online database of brain tissue. Researchers can search the database and apply to BDR for samples.
Start Year 2013
 
Description Brains for Dementia Research 
Organisation University of Manchester
Department Institute of Brain, Behaviour and Mental Health
Country United Kingdom 
Sector Academic/University 
PI Contribution Overall Management of BDR Centre, recruitment and Brain Banking
Collaborator Contribution Overall Management of BDR Centre, recruitment and Brain Banking
Impact BDR aims to set a gold standard for brain donation by coordinating brain banks across the country and providing high quality tissue to researchers. We hope to enable more people to get involved in brain donation, thus boosting the number of brains available for this important research. BDR is unique because every brain donor is monitored throughout their later life. This means that a complete medical history is available to accompany their donated brain tissue. This is crucial to allow researchers to make the most of donated tissue. BDR run an online database of brain tissue. Researchers can search the database and apply to BDR for samples.
Start Year 2013
 
Description Brains for Dementia Research 
Organisation University of Oxford
Department Oxford Parkinson's Disease Centre (OPDC)
Country United Kingdom 
Sector Academic/University 
PI Contribution Overall Management of BDR Centre, recruitment and Brain Banking
Collaborator Contribution Overall Management of BDR Centre, recruitment and Brain Banking
Impact BDR aims to set a gold standard for brain donation by coordinating brain banks across the country and providing high quality tissue to researchers. We hope to enable more people to get involved in brain donation, thus boosting the number of brains available for this important research. BDR is unique because every brain donor is monitored throughout their later life. This means that a complete medical history is available to accompany their donated brain tissue. This is crucial to allow researchers to make the most of donated tissue. BDR run an online database of brain tissue. Researchers can search the database and apply to BDR for samples.
Start Year 2013
 
Description CADR 
Organisation Bangor University
Country United Kingdom 
Sector Academic/University 
PI Contribution sample preparation, data analysis
Collaborator Contribution data analysis, sample collections
Impact none yet
Start Year 2014
 
Description CADR 
Organisation Swansea University
Country United Kingdom 
Sector Academic/University 
PI Contribution sample preparation, data analysis
Collaborator Contribution data analysis, sample collections
Impact none yet
Start Year 2014
 
Description CFAS 
Organisation Bangor University
Country United Kingdom 
Sector Academic/University 
PI Contribution We are working together with CFAS to prepare the 3,000 participant cohort for genetic research.
Collaborator Contribution Provided cohort
Impact CFAS prepared for Genetic analysis
Start Year 2009
 
Description CFAS 
Organisation Swansea University
Country United Kingdom 
Sector Academic/University 
PI Contribution We are working together with CFAS to prepare the 3,000 participant cohort for genetic research.
Collaborator Contribution Provided cohort
Impact CFAS prepared for Genetic analysis
Start Year 2009
 
Description Caerphilly Cohort 
Organisation Cardiff University
Department School of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution AD expertise, Genotyping, Data analysis, study design
Collaborator Contribution DNA, Epidemiological data, data analysis, study design
Impact unknown
Start Year 2012
 
Description Caerphilly Cohort 
Organisation University of Bristol
Department Avon Longitudinal Study of Parents and Children (ALSPAC)
Country United Kingdom 
Sector Academic/University 
PI Contribution AD expertise, Genotyping, Data analysis, study design
Collaborator Contribution DNA, Epidemiological data, data analysis, study design
Impact unknown
Start Year 2012
 
Description Caerphilly Cohort 
Organisation University of Cambridge
Department MRC Cognitive Function and Ageing Study (CFAS)
Country United Kingdom 
Sector Academic/University 
PI Contribution AD expertise, Genotyping, Data analysis, study design
Collaborator Contribution DNA, Epidemiological data, data analysis, study design
Impact unknown
Start Year 2012
 
Description Clinical collection supply agreement to investigate the genetics of Alzheimer's disease 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution We collected 200 AD cases with full clinical work up including volumetric neuroimaging and DNA sampling.
Collaborator Contribution GSK funded the collection and storage of DNA samples and clinical and neuroimaging measures on 200 Alzheimer's disease cases in the early stages of disease.
Impact 17998437 19013250
 
Description Dementia Platform UK (DPUK) 
Organisation Department of Health Social Services and Public Safety (DHSSPS)
Country United Kingdom 
Sector Public 
PI Contribution Biostatistical analysis and epidemiological
Collaborator Contribution sample collections / cohorts, data and molecular biology
Impact none yet
Start Year 2014
 
Description EPAD 
Organisation GlaxoSmithKline (GSK)
Department Epidemiology
Country United Kingdom 
Sector Private 
PI Contribution GENOTYPING AND ANALYSIS
Collaborator Contribution cohorts, biomarker studies, epidemiological studies, random control studies
Impact none yet
Start Year 2014
 
Description Eisai Collaboration 
Organisation Eisai Ltd
Country Japan 
Sector Private 
PI Contribution We are identifying important genes and pathways involved in Alzheimer's disease for further investigation in functional experiments and drug-based tests.
Collaborator Contribution Expertise in functional biology
Impact None yet
Start Year 2015
 
Description Eli Lilly Collaboration 
Organisation Cardiff University
Department School of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution Access to patient bio-samples, co-directs study design
Collaborator Contribution scientific input, co-direct study design, funding
Impact unknown
Start Year 2012
 
Description Eli Lilly Collaboration 
Organisation Eli Lilly & Company Ltd
Country United Kingdom 
Sector Private 
PI Contribution Access to patient bio-samples, co-directs study design
Collaborator Contribution scientific input, co-direct study design, funding
Impact unknown
Start Year 2012
 
Description Finding genes for late onset Alzheimer's disease: Collaboration between Washington University, NIMH, Cardiff University and Celera Diagnostics 
Organisation Quest Diagnostics
Department Celera Diagnostics
Country United States 
Sector Private 
PI Contribution We undertook a genomewide association study of Alzheimer's disease using genetic pooling and also tested associations with candidate genes. The Celera Diagnostics through a sub-contract with MERCK paid for the genomewide association genotyping. Our group took the lead on some studies and contributed samples and intellectual input on others but at all stages all decisions about research design etc were undertaken jointly in a full collaborative fashion. This built on a previous collaboration between ourselves and Allison Goates group from Washington University which spanned over a decade.
Collaborator Contribution Our collaborative group including Celera Diagnostics, Allison Goate and John Hardys research groups undertook a genomewide association study of Alzheimer's disease using genetic pooling and also tested associations with candidate genes. Celera Diagnostics through a sub-contract with MERCK paid for the genomewide association genotyping. Our group took the lead on some studies and contributed samples and intellectual input on others but at all stages all decisions about research design etc were undertaken jointly in a full collaborative fashion. This built on a previous collaboration between ourselves and Allison Goates group from Washington University which spanned over a decade.
Impact 17949987 17492769 17725986 18063669 16161859 16385451 16278862 16847012 17317784
 
Description GENAROAD 
Organisation Genetic Architecture of Rate of Alzheimer’s Decline (GENAROAD) Consortium
Country Global 
Sector Charity/Non Profit 
PI Contribution data and analyses
Collaborator Contribution data analysis
Impact none yet, paper being prepared for publication
Start Year 2013
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Albert Ludwigs University of Freiburg
Country Germany 
Sector Hospitals 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Brigham Young University
Country United States 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Central Institute for Mental Health
Country Germany 
Sector Hospitals 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Free University of Berlin
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Friedrich-Alexander University Erlangen-Nuremberg
Department Department of Psychiatry
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation German Centre for Neurodegenerative Diseases
Country Germany 
Sector Public 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Goethe University Frankfurt
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Helmholtz Association of German Research Centres
Department Helmholtz Zentrum Munchen
Country Germany 
Sector Public 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation King's College London
Department Institute of Psychiatry, Psychology & Neuroscience
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Ludwig Maximilian University of Munich (LMU Munich)
Department Department of Neurology
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Mayo Foundation for Medical Education and Research (MFMER)
Country United States 
Sector Charity/Non Profit 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Medical Research Council (MRC)
Department MRC Centre for Neuropsychiatric Genetics and Genomics
Country United Kingdom 
Sector Public 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation National Institutes of Health (NIH)
Country United States 
Sector Public 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Oxford University Hospitals NHS Foundation Trust
Department NIHR Oxford Biomedical Research Centre
Country United Kingdom 
Sector Public 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Queen's University Belfast
Department Aging group
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Trinity College Dublin
Country Ireland 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University College London
Department Institute of Neurology
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University College London
Department MRC Prion Unit and the Dementia Research Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University Duisburg-Essen
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Bonn
Department Department of Psychiatry
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Bristol
Department Dementia Research Group
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Cambridge
Department Cambridge Institute of Public Health
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Hamburg
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Manchester
Department Neuroscience Research Institute (NRI)
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Nottingham
Department Centre for Genetics and Genomics
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Southampton
Department Clinical and Experimental Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Zurich
Department Functional Genomics Centre Zurich
Country Switzerland 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Washington University in St Louis
Country United States 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD Exome Chip Consortium 
Organisation Autonomous University of Madrid
Country Spain 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Brigham Young University
Country United States 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Cardiff University
Department School of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Fondazione Santa Lucia
Country Italy 
Sector Hospitals 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Hospital de Sant Pau
Country Spain 
Sector Hospitals 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Ludwig Maximilian University of Munich (LMU Munich)
Country Germany 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Neuroscience; IOP
Country United Kingdom 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Queen's University Belfast
Department Aging group
Country United Kingdom 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Saarland University
Country Germany 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University College London
Department MRC Prion Unit
Country United Kingdom 
Sector Public 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Bonn
Department Department of Psychiatry
Country Germany 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Cantabria
Country Spain 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Navarra
Country Spain 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Nottingham
Department Centre for Genetics and Genomics
Country United Kingdom 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Oviedo
Country Spain 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Southampton
Department Clinical and Experimental Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Washington
Country United States 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description Genome-wide Association Studies 
Organisation National Center for Biotechnology Information (NCBI)
Country United States 
Sector Public 
PI Contribution Led and co-ordinated the study that involved the work of the following collaborators: 1 MRC Centre for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine and Neurology, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK. 2 NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, Kings College, London, UK. 3 Department of Neuroscience, Institute of Psychiatry, Kings College, London, UK. 4 Institute of Public Health, University of Cambridge, Cambridge, UK. 5 Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK. 6 Mercer's Institute for Research on Aging, St. James Hospital and Trinity College, Dublin, Ireland. 7 Institute of Genetics, Queen's Medical Centre, University of Nottingham, NG7 2UH, UK. 8 Ageing Group, Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, UK. 9 Division of Clinical Neurosciences, School of Medicine, University of Southampton, Southampton, UK. 10 Clinical Neuroscience Research Group, Greater Manchester Neurosciences Centre, University of Manchester, Salford, UK. 11 Oxford Project to Investigate Memory and Ageing (OPTIMA), University of Oxford, Level 4, John Radcliffe Hospital, Oxford OX3 9DU, UK. 12 Dementia Research Group, University of Bristol Institute of Clinical Neurosciences, Frenchay Hospital, Bristol, UK. 13 Department of Molecular Neuroscience and Reta Lilla Weston Laboratories, Institute of Neurology, London, UK. 14 MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK. 15 Dementia Research Centre, Department of Neurodegenerative Diseases, University College London, Institute of Neurology, London, UK. 16 Department of Psychiatry, University of Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany. 17 Institute of Primary Medical Care, University Medical Center Hamburg-Eppendorf, Germany. 18 Department of Psychiatry, Charité Berlin, Germany. 19 Department of Psychiatry and Psychotherapy, University of Erlangen-Nüremberg, Germany. 20 LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, University Duisburg-Essen, Germany. 21 Institute for Stroke and Dementia Reserach, Klinikum der Universität München, Marchioninistr. 15, 81377, Munich, Germany. 22 Department of Neurology, Klinikum der Universität München, Marchioninistr. 15, 81377, Munich, Germany. 23 Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Square J5, D-68161 Mannheim, Germany. 24 Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience, Laboratory of Neuroimaging & Biomarker Research, Trinity College, University of Dublin, Ireland. 25 Alzheimer Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry, Ludwig-Maximilian University, Munich, Germany. 26 Centre for Geriatric Medicine and Section of Gerontopsychiatry and Neuropsychology, Medical School, University of Freiburg, Germany. 27 Departments of Psychiatry, Neurology and Genetics, Washington University School of Medicine, St Louis, MO 63110, US. 28 Department of Biology, Brigham Young University, Provo, UT, 84602, USA. 29 Neurodegenerative Brain Diseases group, Department of Molecular Genetics, VIB, Antwerpen, Belgium. 30 Institute Born-Bunge and University of Antwerp; Antwerpen, Belgium. 31 Memory Clinic and Department of Neurology, ZNA Middelheim, Antwerpen, Belgium. 32 Department of Mental Health Sciences, University College London, UK. 33 The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK. 34 MRC Centre for Neurodegeneration Research, Department of Clinical Neuroscience, King's College London, Institute of Psychiatry, London, SE5 8AF, UK. 35 3rd Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece. 36 Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, 20892, USA. 37 Department of Genomics, Life & Brain Center, University of Bonn, Sigmund-Freud-Str. 25, D-53127 Bonn, Germany. 38 Institute of Human Genetics, University of Bonn, Wilhelmstr. 31, D-53111 Bonn, Germany. 39 Institute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, University Duisburg-Essen, Hufelandstr. 55, D-45147 Essen, Germany. 40 Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany. 41 Institute of Medical Informatics, Biometry and Epidemiology, Chair of Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany. 42 Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida 32224, USA. 43 Division of Biomedical Statistics and Informatics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Collaborator Contribution This group of 45 collaborators all contributed towards the centres Genome-wide association study
Impact The study, published in Nature Genetics (PubMed ID 19734902), has uncovered two new genes associated with Alzheimer's disease. Previously only one gene, APOE4, had been shown to be a risk factor for Alzheimer's disease. The study reveals, for the first time, that two further genes, CLU and PICALM, are related to Alzheimer's disease. This has led to worldwide media coverage. The data produced is still used in new studies with requests coming in to the host institution every few weeks.
Start Year 2009
 
Description Genomics England 
Organisation Genomics England
Country United Kingdom 
Sector Public 
PI Contribution We are in the very early stages of discussion with Genomics England, but we hope to be able to use their facilities for whole Genome sequencing. This will mean that we generate valuable data on the largest EOAD cohort world-wide.
Collaborator Contribution Genomics England have the equipment and infrastructure set up for the very expensive and technical whole exome sequencing.
Impact None yet
Start Year 2015
 
Description GlaxoSmithKline Cardiff Collaboration 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Prof Williams made contact with a GSK rep at the Global Genetics Congress in Baltimore, September 2016. GSK were extremely interested in collaborating with the Cardiff team. Specifically, GSK have an interest in the latest confidential experimental results and translating these from genetic to biological meaning. This will speed up the Cardiff Team's discovery of potential molecular targets for personalised disease treatment. Cardiff will contribute expertise in Alzheimer's disease genetics.
Collaborator Contribution GSK will contribute their expertise in disease models and drug mechanisms.
Impact This collaboration has been brought under a confidentiality agreement. Parties involved are experts in genetics and functional biology.
Start Year 2016
 
Description International Genomics of Alzheimer's Project (IGAP) 
Organisation Boston University
Country United States 
Sector Academic/University 
PI Contribution Co-leadership, management, DNA from AD cases and controls, GWAS data from AD cases and controls, data analysis and joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation, data analysis
Impact papers in progress
Start Year 2012
 
Description International Genomics of Alzheimer's Project (IGAP) 
Organisation Genetic and Environmental Risk in Alzheimer's Disease (GERAD)
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Co-leadership, management, DNA from AD cases and controls, GWAS data from AD cases and controls, data analysis and joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation, data analysis
Impact papers in progress
Start Year 2012
 
Description International Genomics of Alzheimer's Project (IGAP) 
Organisation University of Lille
Country France 
Sector Academic/University 
PI Contribution Co-leadership, management, DNA from AD cases and controls, GWAS data from AD cases and controls, data analysis and joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation, data analysis
Impact papers in progress
Start Year 2012
 
Description International Genomics of Alzheimer's Project (IGAP) 
Organisation University of Pennsylvania
Department Alzheimer's Disease Genetics Consortium (ADGC)
Country United States 
Sector Learned Society 
PI Contribution Co-leadership, management, DNA from AD cases and controls, GWAS data from AD cases and controls, data analysis and joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation, data analysis
Impact papers in progress
Start Year 2012
 
Description JPND PERADES 
Organisation JPND Research
Country Global 
Sector Academic/University 
PI Contribution Coordinator of the EU Joint Programme - Neurodegenerative Disease Research PERADES project
Collaborator Contribution Containing researchers from 11 countries. Exploiting new statistical approaches to genetic data, researchers will calculate polygenic risk scores and use these to identify individuals at both high and low risk of developing Alzheimer's disease.
Impact The JPND project brings together researchers across Europe to perform vast replication studies of variants of interest in Alzheimer's disease. The project is also the first to begin exome sequencing of the EOAD cohort, which we hope will shed light on the early stages of disease. Importantly, this project brings together the areas of genetics, a variety of omics, polygenic scores, and population studies in a powerful combination to further our knowledge of Alzheimer's disease.
Start Year 2013
 
Description Jackson labs collaboration 
Organisation The Jackson Laboratory
Country United States 
Sector Charity/Non Profit 
PI Contribution We provide the most up to date genetic human Alzheimer's disease study results and interpretation.
Collaborator Contribution Jackson labs provide their expertise in translation of human study findings into small animal transgenic models of genetic diseases.
Impact Attempts so far to tie down both a project plan and committed funding, have not been successful. We are currently exploring alternative methods to whole animal experiments. We hope that in the future we will be able to regenerate interest in this promising collaboration.
Start Year 2016
 
Description MRC AD Cohort 
Organisation King's College London
Department Institute of Psychiatry, Psychology & Neuroscience
Country United Kingdom 
Sector Academic/University 
PI Contribution We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis.
Collaborator Contribution The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.
Impact 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421
 
Description MRC AD Cohort 
Organisation Medical Research Council (MRC)
Department MRC Centre for Developmental Neurobiology
Country United Kingdom 
Sector Public 
PI Contribution We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis.
Collaborator Contribution The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.
Impact 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421
 
Description MRC AD Cohort 
Organisation Trinity College Dublin
Country Ireland 
Sector Academic/University 
PI Contribution We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis.
Collaborator Contribution The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.
Impact 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421
 
Description MRC AD Cohort 
Organisation University of Cambridge
Department Department of Medical Genetics
Country United Kingdom 
Sector Academic/University 
PI Contribution We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis.
Collaborator Contribution The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.
Impact 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421
 
Description MRC AD Cohort 
Organisation University of Cambridge
Department Department of Public Health and Primary Care
Country United Kingdom 
Sector Academic/University 
PI Contribution We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis.
Collaborator Contribution The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.
Impact 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421
 
Description PROTECT / CHARIOT-Pro / Cardiff DPUK 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Genotyping of 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be completed by Cardiff Univ as part of a collaboration funded by Dementias Platform UK. Polygenic risk scores will be calculated for these individuals and data made available via DPUK Platform.
Collaborator Contribution DNA samples from 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be sent to Cardiff Univ for genotyping
Impact None to date - work in progress. Collaboration is multi-disciplinary - Neurology, Neuroepidemiology & Ageing; Genetics & Genomics; Psychiatry
Start Year 2018
 
Description PROTECT / CHARIOT-Pro / Cardiff DPUK 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Genotyping of 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be completed by Cardiff Univ as part of a collaboration funded by Dementias Platform UK. Polygenic risk scores will be calculated for these individuals and data made available via DPUK Platform.
Collaborator Contribution DNA samples from 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be sent to Cardiff Univ for genotyping
Impact None to date - work in progress. Collaboration is multi-disciplinary - Neurology, Neuroepidemiology & Ageing; Genetics & Genomics; Psychiatry
Start Year 2018
 
Description PROTECT / CHARIOT-Pro / Cardiff DPUK 
Organisation University of Exeter
Country United Kingdom 
Sector Academic/University 
PI Contribution Genotyping of 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be completed by Cardiff Univ as part of a collaboration funded by Dementias Platform UK. Polygenic risk scores will be calculated for these individuals and data made available via DPUK Platform.
Collaborator Contribution DNA samples from 1,000 research participants from the PROTECT (KCL & Exeter) and CHARIOT - Pro (Imperial) research studies will be sent to Cardiff Univ for genotyping
Impact None to date - work in progress. Collaboration is multi-disciplinary - Neurology, Neuroepidemiology & Ageing; Genetics & Genomics; Psychiatry
Start Year 2018
 
Description Population Genetics Techologies (PGT) 
Organisation Cardiff University
Department School of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution DNA, AD expertise, data analysis
Collaborator Contribution Next generation sequencing service, bioinformatic study design, data analysis
Impact unknown
Start Year 2011
 
Description Population Genetics Techologies (PGT) 
Organisation Population Genetics Technologies Ltd
Country United Kingdom 
Sector Private 
PI Contribution DNA, AD expertise, data analysis
Collaborator Contribution Next generation sequencing service, bioinformatic study design, data analysis
Impact unknown
Start Year 2011
 
Description Translating the effects of new susceptibility genes for AD into disease mechanisms and potential drug screening 
Organisation Cardiff University
Department School of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution AD expertise, genotying, data analysis, study design, co-supervision of research fellow Amy Gerrish
Collaborator Contribution Functional expertise, study design, co-supervision of research fellow Amy Gerrish
Impact unknown
Start Year 2012
 
Description Translating the effects of new susceptibility genes for AD into disease mechanisms and potential drug screening 
Organisation Severnside Alliance for Translational Research (SARTRE)
Country United Kingdom 
Sector Academic/University 
PI Contribution AD expertise, genotying, data analysis, study design, co-supervision of research fellow Amy Gerrish
Collaborator Contribution Functional expertise, study design, co-supervision of research fellow Amy Gerrish
Impact unknown
Start Year 2012
 
Description UK Biobank neurodenerative disease platform 
Organisation King's College London
Department NIHR Biomedical Research Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution Named investigator on grant application
Collaborator Contribution co-investigators on grant application
Impact Grant application currently under review
Start Year 2013
 
Description UK Biobank neurodenerative disease platform 
Organisation University College London
Department Dementia Research Centre (DRC)
Country United Kingdom 
Sector Academic/University 
PI Contribution Named investigator on grant application
Collaborator Contribution co-investigators on grant application
Impact Grant application currently under review
Start Year 2013
 
Description UK Biobank neurodenerative disease platform 
Organisation University College London
Department Institute of Neurology
Country United Kingdom 
Sector Academic/University 
PI Contribution Named investigator on grant application
Collaborator Contribution co-investigators on grant application
Impact Grant application currently under review
Start Year 2013
 
Description UK Biobank neurodenerative disease platform 
Organisation University of Oxford
Department Department of Physiology, Anatomy and Genetics
Country United Kingdom 
Sector Academic/University 
PI Contribution Named investigator on grant application
Collaborator Contribution co-investigators on grant application
Impact Grant application currently under review
Start Year 2013
 
Description Using worms and flies to screen human genes associated with Alzheimer's disease 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution AD expertise, GWAS data
Collaborator Contribution Functional expertise, Model organisms
Impact unknown
Start Year 2008
 
Description Using worms and flies to screen human genes associated with Alzheimer's disease 
Organisation University of Manchester
Country United Kingdom 
Sector Academic/University 
PI Contribution AD expertise, GWAS data
Collaborator Contribution Functional expertise, Model organisms
Impact unknown
Start Year 2008
 
Title Diagnosis of Alzheimer's Disease 
Description The work has also been published and has achieved a huge amount of media coverage. This discovery of three further genes associated with Alzheimer's disease could provide valuable new leads in the race to find treatments and possibly cures for the devastating condition. This patent application resulted from Julie Williams, Professor of Neuropsychological Genetics and Professor Mike Owen, Professor and Head of MRC Centre, completing the largest-ever joint Alzheimer's disease genome-wide association study (GWAS) involving 16,000 individuals. The patenting of theseSNPS is still in progress and a reveiew is currently underway to identify the best route to exploitation of the technology. 
IP Reference WO2011001135; NZ 596614; CAN 2,766,876; JP 2012-516841 and JP 2013-164509 ;AUS 201001208; US 13/376,485 and US 13/886,473; EP 10747062.7; CN 201080029259.9 and CN 201310280889.9; HK 12110195.8; UK 2766876 
Protection Patent granted
Year Protection Granted 2012
Licensed No
Impact This has had huge worldwide impact through media coverage and was originally highlighted in the press with the discovery of an additional 5 genes. We are currently in the process of seeking a licencee for the patented technology which encompasses a diagnostic test for the protected gene SNPs. Recent advances include generation of a polygenic score including the licensed SNPs for the detection of AD risk. We are working together with industry on basic genetic testing, cohort studies, cognitive test providers and pathway specific therapies for new ways in which to combat Alzheimer's disease.
 
Description 11 new susceptibility genes linked with Alzheimer's disease 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact In the largest ever study of its kind, an international collaboration of scientists, jointly led by Cardiff, has uncovered 11 new susceptibility genes linked with Alzheimer's disease.


Worldwide TV and Newspaper Coverage received
Year(s) Of Engagement Activity 2013
 
Description 2 new genetic variations linked with Alzheimer's 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact An international collaboration of scientists, including expertise from Cardiff University, has uncovered two new genetic variations linked with Alzheimer's, opening up new research avenues into the disease. The two newly discovered genetic variations do not predict a person's risk of developing Alzheimer's, but the authors of the paper, which appears in The Journal of the American Medical Association (JAMA) speak of new valuable insights for scientists working on the disease. Professor Julie Williams, Cardiff University, is a principal investigator of the study, led by Professor Monique Breteler, University Medical Center Rotterdam. The research also builds on the discovery led by Professor Williams last year of the first new genes associated with Alzheimer's in a generation.


Unknown
Year(s) Of Engagement Activity 2010
 
Description 2013 Open Day 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? Yes
Geographic Reach Regional
Primary Audience Undergraduate students
Results and Impact 150 people attended an open day which included a series of talks, poster presentations, lab tours and informal question and answer sessions.

The event was featured on the BBC Radio Wales Science Cafe Show which resulted in increased enquiries from members of the public.
Year(s) Of Engagement Activity 2013
URL http://www.alzheimersresearchuk.org/news-detail/10941/Public-invited-to-day-of-dementia-talks-tours-...
 
Description 5 new Alzheimer's genes 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact A leading University scientist's search for factors that increase the risk of developing Alzheimer's has uncovered five new genes to help pinpoint what's going wrong in the brain. Professor Julie Williams from the University's MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, has identified an additional five new genes - bringing the total number of genes that increase the risk of developing Alzheimer's to ten. (BBC Radio 4, Today programme, BBC Radio Wales, Good Morning Wales, BBC Wales Breakfast News, ITV Wales Breakfast News; BBC On-line, 4.4.2011, www.bbc.co.uk/news/health-12937131; The Mirror, 4.4.11, www.mirror.co.uk/news/top-stories/2011/04/04/genetic-study-uncovers-causes-of-alzheimer-s-disease-115875-23036111/; The Independent, 4.4.11, http://www.independent.co.uk/news/science/a-test-for-alzheimers-disease-ndash-but-will-anyone-want-to-take-it-2261426.html; The Telegraph, 4.4.11, www.telegraph.co.uk/health/healthnews/8422477/New-genes-found-in-hunt-for-Alzheimers-disease-cure.html; Daily Mail, 4.4.11, www.dailymail.co.uk/health/article-1373063/The-genetic-clues-help-prevent-Alzheimers-disease.html?ito=feeds-newsxml;


Unknown
Year(s) Of Engagement Activity 2011
 
Description ART - Westminster 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Dissemination of research findings to parliamentarians

not known
Year(s) Of Engagement Activity 2010
 
Description ART Event - Bournemouth 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Geographic Reach Regional
Primary Audience Participants in your research and patient groups
Results and Impact Disseminating research findings to research participants

not know
Year(s) Of Engagement Activity 2009
 
Description ART Public Lecture 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Presented research findings as part of the ART public lecture "New Alzheimer's genes: What do they mean?"

Not Known
Year(s) Of Engagement Activity 2010
 
Description ARUK 2014 Annual Meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Type Of Presentation keynote/invited speaker
Geographic Reach National
Primary Audience Other audiences
Results and Impact Julie Williams took part in a debate at the 2014 ARUK conference titled: Alzheimer's disease: The relative importance of Genes and Environment

The conference audience took part in the debate and positive feedback was recieved about this part of the conference.
Year(s) Of Engagement Activity 2014
URL http://www.alzheimersresearchuk.org/conference-programme/
 
Description ARUK Iceland donation press release 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact A press release was issued announcing new funding from ARUK raised by Iceland foods

The press release mentioned research investigating Early Onset AD, this resulted in an increase in enquiries about research
Year(s) Of Engagement Activity 2014
URL http://www.alzheimersresearchuk.org/news-detail/10984/Cardiff-researchers-lead-global-hunt-for-early...
 
Description ARUK Public Engagement open day 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Public engagement
Year(s) Of Engagement Activity 2015
 
Description ARUK Scientific meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Other audiences
Results and Impact Scientific meeting
Year(s) Of Engagement Activity 2015
 
Description Alzheimer's Research UK trustee talk and lab tour 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Presentation for lay members of Alzheimer's Research UK

unknown
Year(s) Of Engagement Activity 2012
 
Description Alzheimer's Society legacy event 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Geographic Reach Regional
Primary Audience Supporters
Results and Impact Dr Rebecca Sims spoke at an Alzheimer's Society legacy event

An increase in legacy donations
Year(s) Of Engagement Activity 2013
 
Description Alzheimer's gene study achieves landmark breakthrough 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Cardiff University publicised publication in Nature Genetics "Genetic meta-analysis of diagnosed Alzheimer's disease identifies novel risk loci and implicates Abeta, Tau, immunity and lipid processing" - aiming to raise public awareness of research being undertaken at UK Dementia Research Institute Cardiff
Year(s) Of Engagement Activity 2019
 
Description Alzheimers Society Visit 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Health professionals
Results and Impact presented research findings to representatives of ART at a visit hosted by the Dean of Medicine, Cardiff University

not known
Year(s) Of Engagement Activity 2010
 
Description Annual ART Conference 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Participants in your research and patient groups
Results and Impact Attended and presented at the annual ART conference

not known
Year(s) Of Engagement Activity 2010
 
Description Awarded £800K to lead new genetic research into Alzheimer's 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams, School of Medicine, has been awarded £800K to lead new genetic research into Alzheimer's (Business Weekly, 14.10.10)


Unknown
Year(s) Of Engagement Activity 2010
 
Description BBC (online and local news) 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Prof Julie Williams on AD gene study
Year(s) Of Engagement Activity 2016
URL http://www.bbc.co.uk/news/uk-wales-36286847
 
Description BBC Panorama 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Prof Julie Williams Research Team were approached to be involved in a BBC documentary. The documentary followed one of our research participants and his family through everyday life with Alzheimer's disease. Field workers and laboratory staff were also filmed in their roles. The documentary was screened on BBC1 in Panorama on 2nd June 2016.
Year(s) Of Engagement Activity 2016
 
Description BBC Wales Dementia Week 2016 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Filming with BBC Wales's Owain Clarke on Thursday (12th May, 10-12). Interview is part of a package he's doing for Alzheimer's Awareness Week. Owain will be asking Prof Williams about Wales's research contribution; her own specific research and; look ahead at what's next.
Various excerpts were screened on BBC news throughout the week, featuring a number of different staff from the team at Cardiff. This raised awareness of our work and the profile of the team.
Year(s) Of Engagement Activity 2016
 
Description BBC Wales evening news UK DRI Cardiff official opening 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Interview of Professor Julie Williams to publicise official opening of UK DRI Cardiff. Prof Williams explained the purpose of the DRI, its multi-targeted approach, and the funding that had enabled attraction of world class scientists to Cardiff.
Year(s) Of Engagement Activity 2018
URL https://www.bbc.co.uk/iplayer/episode/b0bp0k0t/bbc-wales-today-evening-news-25102018#
 
Description BBC panorama 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact BBC Panorama are following an EOAD participant. The initial interview was filmed by the BBC
Year(s) Of Engagement Activity 2016
 
Description BBC radio interview 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Radio interview BBC Forty research groups led by scientists in Cardiff, France and the United States have been working more closely together and have now pooled a worldwide database of 90,000 samples. "We're about to submit a paper that is enormously exciting and which I think will really change, without a doubt, what we think of Alzheimer's disease going forward," Professor Julie Williams, head of the research team at Cardiff University, said. "Over the last five or six years we've been successful in identifying 30 genes that increase - or decrease - your risk for Alzheimer's disease. Now this is telling us what some of the major components in disease development are. It's new, it's exciting; it's a different perspective on what Alzheimer's disease is."
Year(s) Of Engagement Activity 2018
URL http://www.bbc.co.uk/news/uk-wales-36286847
 
Description British Neuroscience Conference, Harrogate 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Finding genes for developmental dyslexia

unknown
Year(s) Of Engagement Activity 2011
 
Description British Science Festival 2016 Workshops 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact We used VR tools to demonstrate the impact of dementia on people's everyday lives. These included using the experiences "A Walk Through Dementia", our citizen science game "Sea Hero Quest", some activities from out children's website, as well as hands on activities and memory games.
Year(s) Of Engagement Activity 2016
URL https://www.britishsciencefestival.org/
 
Description Building CanadaUK collaborations in neurodegenerative disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact Seminar at the High Comission of Canada

unknown
Year(s) Of Engagement Activity 2012
 
Description CADR Annual Public Conference, 5th October 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact The Centre for Aging and Dementia Research (CADR) annual public meeting was held on 5th October in City Hall, Cardiff. A variety of individuals attended including the general public, and NHS staff working in dementia. Feedback received indicated that the event was regarded as training for NHS staff. Discussion groups were lively, and focused on clinical dementia. A number of information stands were manned during the meeting, including an ARUK stand, a Cardiff University Alzheimer's Team Recruitment stand, a Join Dementia Research (JDR) Stand, and a variety of others. The Cardiff research team have had an increased number of volunteer queries. We have also furthered collaborations with CFAS Wales, Dr John Hindle (DLB/PD expert) and others as a direct result of this meeting.
Year(s) Of Engagement Activity 2016
URL http://www.cadr.cymru/en/
 
Description CADR Presentation to Minister 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Policymakers/politicians
Results and Impact The Welsh Assembly Government Minister for Health visited Swansea University on 15th August, 2016. CADR staff/scientific leads were asked to prepare short presentations to inform the Minister of the on-going work of the research teams involved in CADR. Prof Julie Williams gave a brief presentation about the research of her team
Year(s) Of Engagement Activity 2016
 
Description CNS Leadership Seminar: The quest to slow Alzheimer's disease progression 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Provided a talk entitled "Genetic basis of Alzheimer disease susceptibility" at the CNS Leadership Seminar: The quest to slow Alzheimer's disease progression

Unknown
Year(s) Of Engagement Activity 2013
URL http://onenucleus.com/onenucleus-events?id=692
 
Description Calling for more funding for research into dementia 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams and Professor Mike Owen, Cardiff University are calling for more funding for research into dementia. (Western Mail, 9/2/11, p5)


Unknown
Year(s) Of Engagement Activity 2011
 
Description Cardiff Scientific Society 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Talk entitled - The Genetics underlying late-onset Alzheimer's Disease

Not Known
Year(s) Of Engagement Activity 2010
 
Description Cardiff experts call for Alzheimer's action 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Cardiff experts have been at the forefront of calls to step up the battle against Alzheimer's Disease in the press and on national television following a leading international conference on the disease. Nationwide media coverage including the BBC news

Will lead to increased public awareness
Year(s) Of Engagement Activity 2010
 
Description Defining the genetic architecture of AD 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Health professionals
Results and Impact Rome 28th February 2011 - Invited speaker


Unknown
Year(s) Of Engagement Activity 2011
 
Description Defining the genetic architecture of Alzheimer's disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Health professionals
Results and Impact Alzheimer's Research Trust Research Day - Manchester ART Centre, Chancellors conference centre 27th January 2011 - Keynote speaker


Unknown
Year(s) Of Engagement Activity 2011
 
Description Defining the genetic architecture of Alzheimer's disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Health professionals
Results and Impact German National Genome Research Network (NGFN) Conference - 27th September 2011 - Keynote speaker


Unknown
Year(s) Of Engagement Activity 2011
 
Description Defining the genetic architecture of Alzheimer's disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Health professionals
Results and Impact College of Mental Health Pharmacy , Leicestershire 30th September 2011 - Keynote speaker


Unknown
Year(s) Of Engagement Activity 2011
 
Description Defining the genetic architecture of Alzheimer's disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Presentation for the Waterloo foundation

unknown
Year(s) Of Engagement Activity 2012
 
Description Defining the genetic architecture of Alzheimer's disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Royal College of Psychiatrists International Congress 29th June 2011 - Invited speaker


Unknown
Year(s) Of Engagement Activity 2011
 
Description Dementia - A National Symposium 2013 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Delivered a talk entitled "Identifying and understanding genes which increase the risk of developing Alzheimer's disease and other dementias"

Unknown
Year(s) Of Engagement Activity 2013
URL http://www.open.ac.uk/science/main/files/science/file/Dementia%202013%20-%20Programme.pdf
 
Description Dementia research at the Cardiff City stadium 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams, School of Medicine, will be among a set of leading speakers discussing dementia research at the Cardiff City stadium today (South Wales Echo, 22.05.11, Pg 10)


Unknown
Year(s) Of Engagement Activity 2011
 
Description Dementia: Making a Difference. Television Programme for BBC2 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Television programme about the work of Julie Williams http://www.bbc.co.uk/programmes/b01j0qwr

unknown
Year(s) Of Engagement Activity 2012
 
Description Distribution of news letter 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? Yes
Geographic Reach Regional
Primary Audience Participants in your research and patient groups
Results and Impact We distribute a 4-8 page newsletter annually to participants in our research, their families and healthcare professionals At present just over 1000 people receive our newsletter.

The newsletter helps engage the public in our research and we receive a large amount of positive feedback from it. We also hope that the newsletter has a positive impact on retention of participants in longitudinal aspects of our research.
Year(s) Of Engagement Activity 2006,2007,2008,2009,2010
 
Description EISA Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Health professionals
Results and Impact Delivered talk entitled - Dementia and Cognitive Dysfunction

Unknown
Year(s) Of Engagement Activity 2010
 
Description Eli Lilly Seminar 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Defining the genetic architecture of Alzheimer's Disease

unknown
Year(s) Of Engagement Activity 2011
 
Description Finding genes for developmental dyslexia 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Health professionals
Results and Impact 7th International Conference - British Dyslexia Association 2 - 5th June 2011 - Invited speaker


Unknown
Year(s) Of Engagement Activity 2011
 
Description Finding the causes of Alzheimer's disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Delivered a public lecture as part of the Science in Health Public Lecture Series entitled "Finding the causes of Alzheimer's disease"

Unknown
Year(s) Of Engagement Activity 2013
URL http://medicine.cf.ac.uk/event/finding-the-causes-of-alzheimers-disease/
 
Description Fiona Phillips visit 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Journalist and broadcaster Fiona Phillips is to visit the University's MRC Centre for Neuropsychiatric Genetics and Genomics this week to investigate leading Alzheimer's research. (South Wales Echo, 21.07.11, p.9)


Unknown
Year(s) Of Engagement Activity 2011
 
Description Funding for Alzheimer's research 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Scientists in Wales researching the causes of dementia are at a "major disadvantage" because the nation does not fund such projects says Professor Julie Williams, School of Medicine. (Western Mail, 4/2/10, p14) Professor Williams is also interviewed about funding for Alzheimer's research.  (BBC Wales News, 4/2/10)


Unknown
Year(s) Of Engagement Activity 2009
 
Description Funding for Alzheimer's research 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams, School of Medicine, is interviewed regarding funding for Alzheimer's research.  (BBC Radio Wales, 2.2.10)


Unknown
Year(s) Of Engagement Activity 2010
 
Description Funding for medical research is dangerously low 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams, School of Medicine, says funding for medical research is dangerously low. (Daily Telegraph 9.2.11 http://www.medicalnewstoday.com/articles/216363.php )


Unknown
Year(s) Of Engagement Activity 2011
 
Description Further insights into the causes of Alzheimer's disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact UN Older Persons' Day - 29th Sept 2011 - Invited speaker


Unknown
Year(s) Of Engagement Activity 2011
 
Description GEHC/CU Symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Local
Primary Audience Third sector organisations
Results and Impact Provided a talk entitled "Opportunities in Wales: WG" at the Joint GE Healthcare / Cardiff University Symposium (Theme: Stem Cell technologies)

Unknown
Year(s) Of Engagement Activity 2013
 
Description Genetic discoveries pinpoint new causes for Alzheimer's disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Alzheimer's Society, Wales Regional Conference 14th July 2011 - Invited speaker


Unknown
Year(s) Of Engagement Activity 2011
 
Description Genetic modifiers workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Progress in neurodegenerative disorders

Unknown
Year(s) Of Engagement Activity 2011
 
Description Genetics of Alzheimer's Disease and its translation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Neurodem Research Development Group presentation on Genetics of Alzheimer's Disease

unknown
Year(s) Of Engagement Activity 2012
 
Description Genome wide association study of Alzheimer's disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Health professionals
Results and Impact Invited Plenary - International Conference on Alzheimer's disease (ICAD) - Vienna - July 2009


Unknown
Year(s) Of Engagement Activity 2009
 
Description Global media coverage 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact In September 2009 we published evidence of two new genes which are associated with susceptibility to Alzheimer's disease. This research generated substantial media interest both nationally and internationally. To see the BBC coverage of this story please visit: http://news.bbc.co.uk/1/hi/wales/8239773.stm. The story was covered in over 70 high quality publications (a full list is provided at the bottom this text). In addition, these findings have recently been recognised as one of the world's top 10 scientific breakthroughs of 2009 by Time magazine. See: http://www.time.com/time/specials/packages/article/0,28804,1945379_1944376_1944408,00.html Publications: Sky News Channel 4 News BBC Wales News ITV Wales Pittsburgh post - Gazette Daily Express Swansea Sound Washington Post New York Times Daily Telegraph Western Mail South Wales Echo The Independent The Irish Times Financial Times Sydney Morning Herald Ottawa Citizen Daily Mail Guardian The Mirror Nottingham Journal The Money Times The Sun Sindh Today Science Daily Belfast Telegraph Emax Health Malaysia News net Digital Journal Cambridge News Online Alzheimer's Society Real Radio Red Dragon Boston Globe Calgary Sun Norwich Evening News The Gov Monitor The Spokesman Review Food consumer Times of India Science News Medical News Today Top News NHS News Nature.com Blog Efitness.now Merinews Science Alert Pulse Today AHN Richmond Times - Dispatch The Birmingham News, Alabama Newsday, Melville NY The San Diego Union - Tribune, California El Nuevo Herald The Daily Gazette, New York St Paul's Pioneer Press Valley News Dispatch Chattanooga Times Free Press St Petersburg Times The Virginian - Pilot The Providence Journal The Gainsville Sun San Jose Mercury News The Journal Gazette Daily Times - Call The Tribune Visit Bulgaria Australian Ageing Agenda The News - Enterprise Ethiopian Review The Times - Tribune, PA South Florida Sun Sentinel ABC7 St Charles County Business Record The St Louis Countian

Such extensive media coverage has raised the profile of Alzheimer's disease and dementia research. Since the articles were published we have received numerous enquiries from members of the public wanting to contribute to our research. It has also promoted our own research nationally and internationally and we have developed collaborations as a direct result of this media coverage.
Year(s) Of Engagement Activity 2009
 
Description Grandround presentation - NHS Cardiff Postgraduate Centre 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Health professionals
Results and Impact Defining the genetic architecture for Alzheimer's Disease

unknown
Year(s) Of Engagement Activity 2011
 
Description Health and Care Research Wales Public Engagement talk 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Institute of Psychological Medicine and Clinical Neurosciences staff at Cardiff University School of Medicine were required to attend a one hour presentation on the importance of engaging with the public in scientific research. The aim was to give staff a greater appreciation of public involvement, and the benefits of this in research.
Year(s) Of Engagement Activity 2016
URL http://www.healthandcareresearch.gov.wales/involving-the-public-in-your-research
 
Description House of Commons presentation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Alzheimer's Disease - causes, research

unknown
Year(s) Of Engagement Activity 2012
 
Description House of Lords Lunch 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Lunch discussion at The House of Lords

unknown
Year(s) Of Engagement Activity 2012
 
Description ICAD, Paris 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Role of the Immune System and Inflammatory Response in the Aetiology of Alzheimer's Disease

unknown
Year(s) Of Engagement Activity 2011
 
Description ITV Wales interview 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Interview with James Crichton-Smith at ITV Wales - ITV Wales are running a piece on early onset Alzheimers.
Year(s) Of Engagement Activity 2015
 
Description ITV Wales interview Dec. 2015 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Interview with James Crichton-Smith at ITV Wales - ITV Wales are running a piece on early onset Alzheimers.
Year(s) Of Engagement Activity 2015
 
Description ITV news interview 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact ITV news interview with Julie Williams discussing research and new funding.

Increase in requests for information from individuals wishing to take part in research
Year(s) Of Engagement Activity 2014
URL http://www.itv.com/news/wales/update/2014-04-03/cardiff-university-leads-new-global-alzheimers-resea...
 
Description IWA's Agenda magazine 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams' Alzheimer's research is featured in the summer edition of IWA's Agenda magazine (Agenda, No 41 Agenda, Front Page and Pgs 48-49)


Unknown
Year(s) Of Engagement Activity 2010
 
Description International Genomics of Alzheimer's Project 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact A group led by Professor Julie Williams, School of Medicine is one of four involved in the International Genomics of Alzheimer's Project - a collaboration formed to discover and map the genes that contribute to Alzheimer's disease. http://www.medicalnewstoday.com/articles/215425.php


Unknown
Year(s) Of Engagement Activity 2011
 
Description Interview for national news 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Official opening of UK DRI Cardiff, attended by 300+ guests, including funders, Welsh government officials, members of the public taking part in dementia research studies, postgraduates. Widely publicised on national BBC and ITV news and radio
Year(s) Of Engagement Activity 2018
URL https://www.bbc.co.uk/news/uk-wales-45942094
 
Description Interview for national news 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Interview on national TV which is broadcast worldwide describing set up of Cardiff Univ receiving funding to set up as a UK dementia centre
Year(s) Of Engagement Activity 2018
URL http://www.bbc.co.uk/news/uk-wales-south-east-wales-39646667
 
Description Interview for regional news 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact Interview on regional news to discuss setting up of new DRI UK laboratories in Cardiff and work on dementia research
Year(s) Of Engagement Activity 2018
URL http://www.itv.com/news/wales/2017-04-20/dementia-centre-to-offer-step-change-in-research/
 
Description Interview with ITV news 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact Julie Williams was interviewed by ITV news in the HEB labs regarding Alzheimer's disease research
Year(s) Of Engagement Activity 2015
 
Description It is time to make mental health research a funding priority 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams, School of Medicine, argues in an essay that it is time to make mental health research a funding priority. Cardiff University has committed to this in creating the new Neuroscience and Mental Health Research Institute - and Professor Williams calls on other decision makers and funders to do likewise. (W.Mail, 9.8.10 p26)


Unknown
Year(s) Of Engagement Activity 2010
 
Description Keynote speech Sutcliffe Kerr Lecture 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact Keynote speech at annual Walton Centre, Sutcliffe Kerr Lecture
Year(s) Of Engagement Activity 2019
 
Description Kings College London Seminar 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Health professionals
Results and Impact Delivered talk entitled - Psychiatric Genetics: Everything you always wanted to know but were afraid to ask

Unknown
Year(s) Of Engagement Activity 2010
 
Description Llandough Hospital 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Health professionals
Results and Impact Dissemination of recent findings

not known
Year(s) Of Engagement Activity 2009
 
Description Local news item on brain donation for dementia research 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Older people in Wales are being urged to think about donating their brains after they die to help scientists researching dementia. This has sparked questions and debates - 80 comments within 24 hours. It will definitely influence people by raising awareness of the disease, the process of donation, benefits of donation/research and also opting in/out law change. We are confident this will increase the number of healthy/diseased donations and positively impact research field.
Year(s) Of Engagement Activity 2018
URL http://www.bbc.co.uk/news/uk-wales-43084710
 
Description MRC CNGG/NCMH/CADR stand at the Wales Gene park's Genetics and Genomics Conference 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Representatives from the Alzheimer's Genetics Team manned a stand at the Wales Gene Park's Genetics and Genomics Conference on 22nd June, 2016. A number of individuals were interested in discussing the research environment, and how participants could help with discovery science.
Year(s) Of Engagement Activity 2016
URL https://www.eventbrite.co.uk/e/genetics-and-genomics-for-the-3rd-generation-tickets-24871582573
 
Description Marshall Scholars 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact A talk entitled "New genetic findings in Alzheimers Disease" was presented to a group of Marshall Scholars

not known
Year(s) Of Engagement Activity 2010
 
Description Medical Women's Federation Spring Conference 2018 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presentation on 'Finding the causes of Alzheimer's disease'
Year(s) Of Engagement Activity 2018
 
Description NGFN Symposium - Bonn 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Health professionals
Results and Impact Delivered talk entitled - Molecular Genetics in Alzheimer's Dementia

Unknown
Year(s) Of Engagement Activity 2010
 
Description New Alzheimer's genes revealed 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Two potentially key genes linked to the development of Alzheimer's disease have been uncovered by UK researchers. Covered by major news channels including the BBC

Nationwide media coverage will lead to increased public knowledge
Year(s) Of Engagement Activity 2010
 
Description New Alzheimer's risk genes discovered in record study 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact A press release was issued highlighting the discovery of 11 new susceptibility genes for AD by the IGAP consortium.

Details of these findings were published by all of the main UK news organisations.
Year(s) Of Engagement Activity 2013
URL http://www.cardiff.ac.uk/news/articles/new-alzheimers-risk-genes-discovered-in-record-study-11975.ht...
 
Description New breakthrough in Alzheimer's research 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams, School of Medicine, comments on a new breakthrough in Alzheimer's research which has seen scientists unravel the precise function of genes known to make people more at risk of developing the illness. (Daily Express, 28.10.11, p.17)


Unknown
Year(s) Of Engagement Activity 2011
 
Description New susceptibility genes for Alzheimer's disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Health professionals
Results and Impact Invited speaker - Eisai Symposium in Neuroscience (Dementia and Cognitive Dysfunction) - May 2010


Unknown
Year(s) Of Engagement Activity 2010
 
Description Oxford Seminar Series 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Health professionals
Results and Impact Invited speaker - Seminar Series,University of Oxford - June 2010


Unknown
Year(s) Of Engagement Activity 2010
 
Description Plenary Speaker at the Alzheimer's Association International Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The plenary speech described our scientific advances in gene discovery and AD risk prediction. This reached an audience of several thousand researchers, clinicians, families, policy makers and funders in the dementia area.
Year(s) Of Engagement Activity 2017
 
Description Pratchett play for Alzheimer's 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact A researcher at Cardiff University's National Centre for Mental Health has produced a play adapted from a Terry Pratchett novel in a bid to raise money for Alzheimer's Research UK.


Unknown
Year(s) Of Engagement Activity 2013
URL http://www.cardiff.ac.uk/news/articles/pratchett-play-for-alzheimers-11246.html
 
Description Presentation and Questions at Carers Group. Participant = Alun Meggy (AD Team) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Carers attend weekly groups that cover a variety or topics about dementia. We were invited to talk about research. The group organiser asked for a further talk in the future
Year(s) Of Engagement Activity 2017
 
Description Presentation and Questions at Torfaen Carers Centre. Participants = Alun Meggy, Jack Beaumont (AD Team) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Study participants or study members
Results and Impact People with dementia and their carers/ families attended a talk to understand why research is important in the field of dementia
Year(s) Of Engagement Activity 2017
 
Description Probus Cardiff 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Provided a talk at the Combined Probus Club of Cardiff Inc.

Increased public awareness of Alzheimer's research
Year(s) Of Engagement Activity 2012
 
Description Public Meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact We hosted a public meeting, supported by the Alzheimer's Research Trust, in September 2007. In addition to events hosted within the University we have also presented our research findings to carers, and individuals with AD at Alzheimer's Society regional meetings in Cardiff, Swansea, Blackwood and Caerleon and to the members of the Newport Carers Group and County Hosptial Carers Group, Pontypool.

These meetings contribute substantially to engaging the public in our research.
Year(s) Of Engagement Activity 2007
 
Description Quote for This is Wales publication 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Quotation provided on the subject of innovation in Wales for trade magazine, emphasising research focus on dementia, specifically Alzheimer's disease
Year(s) Of Engagement Activity 2018
 
Description Radio Cymru Discussion on Alzheimer's disease. Participant = Alun Meggy, AD Team 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Mr Alun Meggy took part in a Welsh discussion group broadcast live on Radio Cymru on 17th February 2017. Alun spoke in Welsh regarding Alzhiemer's disease research, and how we are working hard to develop our knowledge of this debilitating disease.
Year(s) Of Engagement Activity 2017
 
Description Radio discussion 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact BBC Radio Wales Jason Mohammed show discussing progress in Alzheimer's Disease Research

unknown
Year(s) Of Engagement Activity 2012
 
Description Recorded interview ARUK conference March 2018 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact An interview with Video Journal Dementia at ARUK Conference 2018 discussing work at Cardiff DRI UK - online publication aimed at healthcare professionals
Year(s) Of Engagement Activity 2018
URL https://vjdementia.com/speaker/julie-williams
 
Description Researchers Find Two More Genetic Risk Factors For Alzheimer's Disease 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Widespread worldwide broadcast, press and online coverage of a major new study into Alzheimer's led by researchers at Cardiff University. Including BBC, Channel 4, SKY and ABC news, The Telegraph, The Times, The Telegraph, The New York Times and all over major news channels / papers.

"The MRC Centre and research like this is changing our understanding of what causes the common form of Alzheimer's disease and provides valuable new leads in the race to find treatments and possibly cures.

"It also shows that other genes can be identified using this method, and we are already planning a larger study involving 60,000 people, which can be achieved within the next year.

"It is also important to recognise the contribution many Welsh people who have acted as subjects for this research over the years."
Year(s) Of Engagement Activity 2009,2010
 
Description Rugby legend's research donation 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact A Wales and British Lions rugby legend will help boost the University's world-leading Alzheimer's research by chipping-in with a charity donation.

Charitable donation received
Year(s) Of Engagement Activity 2013
URL http://www.cardiff.ac.uk/news/articles/rugby-legends-research-donation-9461.html
 
Description SciScreen Dementia Event 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Dr Rebecca Sims gave a public presentation on Dementia research before a free screening of the film "Away from Her", post-film discussion and free drinks reception. The purpose of the event is for scientists to engage with the general public for mutual benefit. The presentation was well received, and the discussions were lively.
Year(s) Of Engagement Activity 2016
 
Description Science Cafe talk 10th May 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact A talk was given by PhD student and Neurologist, Dr Jude Harrison. Science Cafe events are designed to encourage the general public to engage with science in an informal environment.
Year(s) Of Engagement Activity 2016
 
Description Scientists at Cardiff University say they are a step closer to understanding the causes of dementia 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Scientists at Cardiff University say they are a step closer to understanding the causes of dementia, thanks to a grant of nearly £250,000. The money will fund its brain bank, a centre which encourages people to donate their brains for medical research. Professor Julie Williams comments (BBC Wales On-line, 04.07.2013

Unknown
Year(s) Of Engagement Activity 2013
URL http://www.bbc.co.uk/news/uk-wales-22288025
 
Description Seven preventable risk factors which can be attributed to Alzheimer's disease 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams, School of Medicine, comments on a new study by scientists in the US which shows seven preventable risk factors which can be attributed to Alzheimer's disease. (Western Mail, 20.07.11, p.10); (South Wales Echo, 20.07.11, p.20)


Unknown
Year(s) Of Engagement Activity 2011
 
Description Tenby Observer 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Talk by Prof Julie Williams (at Oriel y Parc, 5 Aug) advertised
Year(s) Of Engagement Activity 2016
URL http://www.tenby-today.co.uk/article.cfm?id=105748&headline=Oriel%20y%20Parc%20to%20host%20second%20...
 
Description The Academy of Medical Sciences, Cardiff 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Successful collaborations with basic scientists


unknown
Year(s) Of Engagement Activity 2011
 
Description The Alzheimer's Society first all-Wales conference in Swansea 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams, School of Medicine, was a keynote speaker on the genetic causes of Alzheimer's at the Alzheimer's Society first all-Wales conference in Swansea. (W.Mail 12.7.11 p12)


Unknown
Year(s) Of Engagement Activity 2011
 
Description The First Minister for Wales Carwyn Jones has appointed Cardiff University's Professor Julie Williams, School of Medicine, as Wales' Chief Scientific Adviser. 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact The First Minister for Wales Carwyn Jones has appointed Cardiff University's Professor Julie Williams, School of Medicine, as Wales' Chief Scientific Adviser.

Unknown
Year(s) Of Engagement Activity 2013
 
Description The International Genomics of Alzheimer's Project (IGAP) 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact A leading University expert in identifying genes that cause Alzheimer's disease will meet with some of the world's other figures for the first-time in Paris (Friday 19th November) in a bid help share knowledge and speed-up the genetic fight against the disease. The International Genomics of Alzheimer's Project (IGAP) is a major international consortium which brings together for the first time four of the world's leading research centres - including  Professor Julie Williams, School of Medicine, who leads the Genetic and Environmental Risk in Alzheimer's Disease (GERAD).


Unknown
Year(s) Of Engagement Activity 2010
 
Description The International Genomics of Alzheimer's Project (IGAP) 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact The International Genomics of Alzheimer's Project (IGAP) - a group of leading experts in Alzheimer's research from Europe, USA and the rest of the world has been established. The new international group includes Professor Julie Williams, School of Medicine (PR Newswire, 01.02.11, www.prnewswire.com/news-releases/first-international-collaboration-on-the-genetics-of-alzheimers-disease-is-launched-114989074.html)


Unknown
Year(s) Of Engagement Activity 2011
 
Description The Today Programme 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact JW on BBC Radio 4's Today programme talking
about her discovery of two new genes associated with Alzheimer's disease which could provide
valuable new leads in the race to find treatments and possibly cures for the devastating condition

Unknown
Year(s) Of Engagement Activity 2009
 
Description Time Magazine - Medical breakthroughs of 2009 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact A key University study which helped uncover two new genes associated with Alzheimer's disease has been recognised as one of the top 10 medical breakthroughs of 2009 by TIME Magazine.

International acknowledgement of research findings.
Year(s) Of Engagement Activity 2009
 
Description U3A Brecon 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Participants in your research and patient groups
Results and Impact Dissemination of Alzheimers research findings

not known
Year(s) Of Engagement Activity 2010
 
Description UN Older Persons Day - Cardiff 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Delivered talk entitled - Will identifying susceptibility genes for Alzheimer's Disease increase healthy aging?

Unknown
Year(s) Of Engagement Activity 2010
 
Description US Fulbright Scholars Forum 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Spoke at the US Fulbright Scholars Forum .
Each year the Fulbright Awards team organise a week-long Forum for current US postgraduates and scholars to get together and explore a different part of the country. This January, over fifty grantees descended on the cities of Bristol and Cardiff to explore Wales and the West Country. Fulbright was generously hosted by the University of Bristol and the University of Cardiff who helped put on an excellent series of events.

Unknown
Year(s) Of Engagement Activity 2013
URL https://www.bfsa.org/wales
 
Description Un o Bob Tri (One of Every Three) Television Programme for S4C 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact Interview for TV programme http://www.s4c.co.uk/ffeithiol/e_un_bob_tri.shtml

unknown
Year(s) Of Engagement Activity 2012
 
Description University's work on Alzheimer's 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams, School of Medicine, discusses the University's work on Alzheimer's. (BBC Radio Wales 17.2.11)


Unknown
Year(s) Of Engagement Activity 2011
 
Description Update on medical and scientific advances in prevention and treatment of dementia 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Health professionals
Results and Impact UK dementia Congress Plenary: Update on medical and scientific advances in previention and treatment of dementia

unknown
Year(s) Of Engagement Activity 2012
 
Description WAG Seminar 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Policymakers/politicians
Results and Impact Presented recent research findings to policy makers

not known
Year(s) Of Engagement Activity 2010
 
Description Wales Gene Park 10th Anniversary, Cardiff "Defining the genetic architecture of Alzheimer's disease" 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Provided a talk entitled "Defining the Genetic Architecture of Alzheimer's Disease"

Unknown
Year(s) Of Engagement Activity 2013
URL http://www.walesgenepark.cardiff.ac.uk/wp-content/uploads/2013/04/4_Julie_Williams.pdf
 
Description Welsh language champions in NHS health boards 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Media (as a channel to the public)
Results and Impact Professor Julie Williams, School of Medicine comments on plans to appoint Welsh language champions in NHS health boards. (Western Mail, 7/6/10, p25)


Unknown
Year(s) Of Engagement Activity 2010
 
Description Welsh presentation (Cardiff Science Society) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact A presentation was given in Welsh, by Alzheimer's Field Worker, Alun Meggy to the Cardiff Science Society on 21st November 2016. This was followed by questions and a discussion.
Year(s) Of Engagement Activity 2016
URL http://www.cymdeithaswyddonolcaerdydd.org
 
Description Western Mail/ Wales online interview 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact An article was published online and in print

not known
Year(s) Of Engagement Activity 2012
URL http://www.walesonline.co.uk/lifestyle/showbiz/how-professor-julie-williams-went-2017479
 
Description Westminster visit - Dementia 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Dissemination of research findings to parliamentarians

not known
Year(s) Of Engagement Activity 2009
 
Description Will identifying susceptibility genes for Alzheimer's disease increase healthy ageing? 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Invited speaker - United Nations Older Person's Day - Promoting active and healthy ageing - Cardiff, 30th September 2010


Unknown
Year(s) Of Engagement Activity 2010
 
Description Will members of my family develop Alzheimers disease?' 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Dr Rebecca Sims presented "Will members of my family develop Alzheimer's disease?" at CADR Meeting Swansea, 2/8/2018. This reached an audience of 50 persons including general public, medical professionals, researchers and carers. This generated a number of questions and discussion after the talk, and was part of a wider discussion following other presentations focusing on similar topics.
Year(s) Of Engagement Activity 2018
 
Description Young Onset Dementia: Different impact, positive solutions conference 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact This public meeting was held on 27th September, 2016. This was a recruitment opportunity.
Year(s) Of Engagement Activity 2016
URL https://www.youngdementiauk.org/sites/default/files/Young%20Dementia%202016%20programme.pdf
 
Description Zeurs Austria - Drugs Genetics 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Presented talk entitled - Defining the genetic architecture for AD

not known
Year(s) Of Engagement Activity 2009
 
Description alt.Cardiff blog entry 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Journalist Jessica Phillips interviews Julie Williams for an article on her blog
Year(s) Of Engagement Activity 2015
 
Description the country needs more scientists 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Wales' new chief scientific adviser, Prof Julie Williams, says the country needs more scientists. The Merthyr-born academic was appointed a CBE for her Alzheimer's research at the School of Medicine in Cardiff, and her appointment was announced last month (BBC Wales Today; BBC Wales On-line, 16.09.2013

Unknown
Year(s) Of Engagement Activity 2013
URL http://www.bbc.co.uk/news/uk-wales-24111210#?utm_source=twitterfeed&utm_medium=twitter